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Pr esen tation of C a se
A 46-year-old woman was referred to a rheumatologist at this hospital because of 
swelling of the legs and skin changes.
The patient had been in her usual state of health until approximately 2 years 
earlier, when she was admitted to another hospital because of painful swelling of 
the left leg. She had been using oral contraceptives for 6 months for control of men-
orrhagia. She had chronic kidney disease caused by congenital ureteral reflux, which 
had not required dialysis; she was seen regularly by a nephrologist. Magnetic reso-
nance imaging (MRI) with angiography revealed thrombosis of the left common iliac, 
internal and external iliac, and common femoral veins. MRI of the chest with an-
giography showed no evidence of pulmonary embolism. Laboratory evaluation showed 
no evidence of hypothyroidism, no abnormalities of coagulation factor II or V, and 
normal levels of protein C, protein S, and antithrombin 3; tests for anticardiolipin 
antibodies and lupus anticoagulant were negative. Oral contraceptives were dis-
continued, and anticoagulation was begun with heparin, followed by warfarin.
Approximately 7 weeks later, swelling of the left leg increased, associated with 
a pruritic rash on the left medial thigh. Imaging studies reportedly showed reca-
nalization of the proximal superficial femoral vein and were otherwise unchanged. 
Doxycycline and azithromycin were administered but discontinued after testing for 
Lyme disease was negative. Antinuclear-antibody titers were negative, and the level 
of d-dimer was normal. She saw a dermatologist, and punch-biopsy specimens of 
the skin of the left thigh and calf were reported to show numerous eosinophils, a 
feature consistent with a hypersensitivity reaction.
Swelling of the left leg persisted. On examination 6 months after the onset of 
symptoms, there was pitting edema (1+) of the left leg. The right calf was 32 cm 
in circumference and the left 35 cm. The skin had a bluish discoloration, and 
peripheral pulses were normal. Noninvasive vascular studies showed no evidence 
of deep venous thrombosis. Warfarin was discontinued after approximately 8 months 
of anticoagulation. One month later, swelling of the left leg worsened. On exami-
nation, there was mild edema extending from the left ankle to the mid-thigh, with 
erythematous discoloration of the skin in a reticular pattern, with atrophie blanche 
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at the edges. Noninvasive vascular studies dis-
closed recurrent deep venous thromboses in the 
left popliteal and calf veins, and anticoagulation 
with enoxaparin and warfarin was begun. Swell-
ing of the left leg and reticular erythema of the 
skin persisted.
Approximately 7 months before evaluation at 
this hospital, the patient noted a sensation of 
tightness in both legs after prolonged exercise, 
followed by thickening of the skin of the left up-
per thigh that progressed to involve the calf. On 
examination 6 weeks later, there was diffuse ery-
thema and thickening of the skin of the left leg, 
extending from the lower calf to the thigh; the 
skin of the right calf was thickened, without ery-
thema. The hematocrit was 34%; the remainder of 
the complete blood count was normal, as were the 
erythrocyte sedimentation rate, the creatine kinase 
level, and testing for antinuclear antibodies. Patho-
logical examination of a specimen from a deep-
wedge biopsy of the left thigh revealed septal 
panniculitis with fibrosis and an inflammatory 
infiltrate including lymphocytes, eosinophils, and 
histiocytes with occasional giant cells, features 
thought to be consistent with erythema nodosum, 
a hypersensitivity reaction, or eosinophilic fascii-
tis. Treatment with prednisone (60 mg daily) was 
begun, and the patient reported decreased erythe-
ma and discomfort. Four months later, hemodi-
alysis was initiated because of metabolic acidosis. 
Administration of mycophenolate mofetil (1000 mg 
daily) was begun, and prednisone was tapered to 
10 mg daily. She was referred to a rheumatologist 
at this hospital.
She reported occasional spasms of her fingers 
during dialysis, mild joint pain, and fatigue but 
no joint stiffness, morning stiffness, hyperpig-
mentation, or woody changes of the skin. She re-
ported difficulty walking, bending to the floor, 
getting in and out of an automobile, and fatigue 
after walking 2 miles. She had chronic obstruc-
tive nephropathy due to congenital bilateral ure-
teral reflux, with tubular acidosis and secondary 
hyperparathyroidism. A neobladder had been con-
structed 20 years earlier. She had had a cholecys-
tectomy and a cesarean section. She did not re-
call having been exposed to gadolinium. She had 
been adopted as a child. Her biologic mother had 
died in her 50s of vulvar carcinoma; a biologic 
uncle had died of colon cancer, and maternal 
grandparents had lived into their 80s. There was 
no known family history of hematologic, renal, 
or rheumatic diseases. She lived with her husband 
and son and worked in an office. She drank al-
cohol rarely and did not smoke. She was allergic 
to penicillin, sulfa, nitrofurantoin, and vancomy-
cin. Medications included warfarin, levothyroxine, 
sodium bicarbonate, calcitriol, calcium carbonate, 
prednisone, mycophenolate mofetil, and weekly 
darbepoetin alfa injections.
On examination, she was cushingoid. Vital 
signs were normal. There was mild erythema over 
the cheeks. The conjunctivae and sclera were nor-
mal. There were no oral or nasal ulcerations. There 
was slight erythema over an area of swelling on 
the left lower leg but no hyperpigmentation, teth-
ering of the skin to the underlying fascia, peau 
d’orange change, or hair loss. A dialysis catheter 
was present in a right upper intercostal space, and 
an arteriovenous fistula was present in the left 
antecubital fossa. There was full motion of all 
joints, without inflammation or deformity. The 
remainder of the examination was normal. She 
was advised to continue immunosuppressive ther-
apy and to avoid radiologic studies with gado-
linium. She was placed on a waiting list for a renal 
transplant. The next month, mycophenolate mofetil 
was discontinued because of thrombocytopenia. 
During the next year, the skin lesions were un-
changed.
Approximately 14 months after presentation, 
difficulty swallowing (first solid foods, then liq-
uids) developed, and she noted increasing tight-
ness in both legs. On examination by a dermatolo-
gist, there was induration of the left leg, extending 
to the mid-thigh, without brawny discoloration, 
and prominent telangiectasias over the cheeks. 
At this time, review of her records disclosed that 
the patient had received gadolinium contrast ma-
terial for MRI studies in the past on three occa-
sions; the patient was informed of this. One month 
later, she returned to the rheumatology clinic.
She had recently noted hyperpigmentation of 
the skin of the left thigh, both lower legs, and 
left forearm and reported morning stiffness and 
increased difficulty walking. On examination, 
there was hyperpigmentation of the skin of both 
legs (Fig. 1A and 1B) and the left forearm, teth-
ering of the skin to the underlying fascia, and no 
peau d’orange change. There were bilateral nasal 
and temporal yellow scleral plaques (Fig. 1C). 
There were no joint contractures. The remainder 
of the physical and neurologic examinations was 
normal. A diagnostic procedure was performed.
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Differ en ti a l Di agnosis
Dr. Daniela Kroshinsky: This patient presented with 
swelling of the leg, followed by cutaneous, ocu-
lar, and systemic findings, including progressive 
hardening or induration of the skin with hyper-
pigmentation and telangiectasias, yellow scleral 
plaques, and difficulty walking, bending, and swal-
lowing. I will approach this case by considering 
the differential diagnosis first of progressive in-
duration of the skin and then of the cutaneous 
manifestations of renal disease.
Progressive induration of the skin
Progressive induration of the skin may be caused 
by immunologic or inflammatory disorders, met-
abolic disorders, depositional disorders, or expo-
sures to toxins. Immunologic or inflammatory 
causes include eosinophilic fasciitis, graft-versus-
host disease, lichen sclerosus et atrophicus, sys-
temic lupus erythematosus, dermatomyositis, and 
scleroderma. Metabolic conditions include por-
phyria cutanea tarda, myxedema of hypothyroid-
ism, and phenylketonuria. There are several dis-
orders in which abnormal deposits are associated 
with skin induration, including scleromyxedema, 
amyloidosis, nephrogenic systemic fibrosis, sclere-
dema, and lipodermatosclerosis. Finally, exposure 
to certain toxins such as l-tryptophan or toxic 
oils can cause induration of the skin.
In view of the patient’s history and clinical 
appearance (no history of transplantation or di-
rect exposure to toxins; localization to the arms 
and legs; lack of blistering, scarring, hypertricho-
sis, or multiorgan dysfunction; and onset in adult-
hood), we can eliminate graft-versus-host disease, 
lichen sclerosus et atrophicus, porphyria cutanea 
tarda, amyloidosis, and phenylketonuria. Assum-
ing her laboratory values are correct, we can also 
eliminate systemic lupus erythematosus, derma-
tomyositis, and myxedema, leaving us with a dif-
ferential diagnosis that includes eosinophilic fas-
ciitis, lipodermatosclerosis, nephrogenic systemic 
fibrosis, scleredema, scleroderma, and scleromy x-
edema.
Cutaneous manifestations of renal disease
Cutaneous manifestations of renal disease include 
bullous disease of hemodialysis, metastatic calci-
fication, nephrogenic systemic fibrosis, perforat-
ing disorders, pseudoporphyria, and prurigo nod-
ularis, the prurigo nodularis often resulting from 
uremic pruritus. This patient has no vesicles or 
bullae to suggest bullous disease of hemodialysis 
or pseudoporphyria. There are no nodules, crust-
ed lesions, excoriations, or reports of pruritus to 
suggest a perforating disorder, prurigo nodular-
is, or uremic pruritus. The diagnoses that remain 
are scleroderma, eosinophilic fasciitis, sclerede-
ma, scleromyxedema, lipodermatosclerosis, met-
astatic calcification, and nephrogenic systemic 
fibrosis.
Scleroderma
The presence of skin induration and dysphagia in 
a 46-year-old woman raises the possibility of scle-
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Figure 1. Clinical Photographs of the Patient at the Second Rheumatology Visit.
Thickening and discoloration of the skin of the legs are seen, more on the left than on the right (Panel A). Irregular 
erythema of the skin of the left leg is evident (Panel B). There are yellow scleral plaques on both eyes and telangi-
ectasias on the face (Panel C).
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roderma, which is an autoimmune disease that is 
most often seen in women aged 30 to 50 years 
and can affect the skin, blood vessels, and inter-
nal organs.1 The diffuse form often involves both 
distal and proximal limbs, the face and trunk,1,2 
and internal organs and has an increased associ-
ated mortality rate as compared with the limited 
form.1 The limited form tends to involve the dis-
tal limbs and face and has a lower risk of inter-
nal-organ involvement. For the diagnosis of scle-
roderma, the American College of Rheumatology 
requires one major criterion (symmetric sclerosis 
proximal to the metacarpophalangeal or meta-
tarsophalangeal joints) or two minor criteria; the 
minor criteria are sclerodactyly, digital pitting 
scars or loss of substance from the finger pad, 
and bibasilar pulmonary fibrosis.1 This patient 
had involvement of the proximal and distal limbs 
but sparing of the face and trunk, and she had no 
skin changes to the digits or pulmonary problems. 
Cutaneous scleroderma may be preceded by an 
edematous phase that may include digital pitting 
edema but not the diffuse leg edema that this 
patient had.1 Features of cutaneous scleroderma 
are cutaneous induration and dyspigmentation 
(e.g., diffuse hyperpigmentation accentuated over 
areas of pressure, leukoderma with perifollicular 
sparing, telangiectasias on the lips and palms, 
prominent nail-fold capillary loops alternating with 
areas in which the nail-fold capillaries are not 
visible, calcinosis cutis near joints or over distal 
digits, and hypohidrosis) and Raynaud’s phenom-
enon,1 which this patient did not have. Labora-
tory abnormalities in scleroderma include positive 
tests for antinuclear antibody, antineutrophil cy-
toplasmic antibody, and antitopoisomerase (Scl-70); 
this patient was tested only for antinuclear anti-
bodies, which were absent. Of the systemic symp-
toms that can accompany scleroderma, this patient 
reported only dysphagia, and the renal findings 
were attributable to congenital renal disease.
Eosinophilic Fasciitis
Eosinophilic fasciitis is characterized by symmet-
ric, rapidly progressive swelling and thickening of 
the skin of the limbs and sometimes the trunk.1,2 
It classically spares the epidermis, causing it to 
appear wrinkled on examination.3 It is not clear 
from the history whether this finding was elicit-
ed on examination of our patient’s skin. Eosino-
philic fasciitis has been reported to occur after 
vigorous exertion, which our patient reported, or 
after exposure to a toxin such as l-tryptophan or 
rapeseed oil.3,4 Dimpling or a peau d’orange tex-
ture can be seen on the skin and is caused by 
focal dermal tethering to the underlying fascia by 
sclerotic bands; this patient lacked these signs.2,4 
Patients may have an elevated erythrocyte sedi-
mentation rate, eosinophilia, or both, but our pa-
tient did not.2-4 Eosinophilic fasciitis can have as-
sociated systemic findings such as synovitis or 
arthritis, joint contractures, restrictive lung disease, 
pleural effusions, monoclonal gammopathies, and 
multiple myeloma.2-4 She had no physical find-
ings or symptoms to suggest these conditions, 
and she had not been evaluated for a monoclonal 
gammopathy.
Scleredema
Scleredema presents as a diffuse hardening of the 
skin of the upper body due to increased produc-
tion of mucin and collagen without an increased 
number of fibroblasts. Types I and II are charac-
terized by induration of cervicofacial skin that 
can progress to involve the trunk, proximal up-
per arms, and face,3 often resulting in masklike 
facies associated with difficulty opening the mouth. 
Type I is most often seen in women and children 
after an upper respiratory infection, especially of 
streptococcal origin, and resolves spontaneously 
over a period of months, whereas type II is idio-
pathic, is slower in onset and resolution, and can 
be associated with a monoclonal gammopathy.1,3 
Type III (scleredema diabeticorum) presents as 
hardening and erythema of the skin of the poste-
rior neck and upper back in middle-aged men 
with diabetes; it results from irreversible glycosy-
lation of collagen fibers that reduces their colla-
genase-mediated degradation.1,3 All types can have 
systemic involvement, with dysphagia, dysarthria, 
serositis, and myositis, as well as cardiac and ocu-
lar changes.1,3 Other than dysphagia, these find-
ings do not fit this patient’s clinical scenario.
Scleromyxedema
Scleromyxedema is characterized by monomorphic 
small papules that may be edematous, indurated, 
erythematous, or hyperpigmented; they occur in a 
symmetric and commonly linear distribution over 
the hands, forearms, head, neck, upper trunk, and 
thighs and are surrounded by shiny, indurated 
skin.1,3 Scleromyxedema is a disorder of increased 
fibroblast proliferation and deposition of mucin 
and collagen. Involvement of the glabella produces 
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classic linear furrows, whereas thickening of the 
skin over the proximal interphalangeal joints pro-
duces the “doughnut sign,” a central depression 
with an elevated, firm rim of skin when these 
joints are extended.1,3 The cutaneous findings in 
our patient do not support this diagnosis. It can 
be associated with several systemic findings, in-
cluding dysphagia, as our patient had, proximal 
muscle weakness, peripheral neuropathy, arthrop-
athy, lung and renal disease, and monoclonal 
gammopathy.1,3 Although the patient’s difficulty 
getting into or out of a chair could be due to prox-
imal muscle weakness, it appears to be related 
more to skin hardening over her joints, since she 
also reported difficulty bending and walking.
Lipodermatosclerosis
Long-standing venous insufficiency can induce a 
panniculitis that heals with sclerosis and indura-
tion of the skin of the medial leg, a condition 
known as lipodermatosclerosis. It traditionally af-
fects the area just above the malleolus.5,6 This 
condition is most often seen in women over 40 
years of age and can occur in any dependent site. 
In its acute phase, lipodermatosclerosis presents 
with pain, warmth, erythema, and induration of 
the affected areas.6 As this condition progresses 
to dermal and subcutaneous sclerosis in the chron-
ic phase, a sharply demarcated area of induration 
develops, with hyperpigmentation due to hemo-
siderin deposition.5,6 When the condition is  pro-
nounced, the lower legs can resemble an “invert-
ed champagne bottle.”5 Lipodermatosclerosis is 
usually not progressive and would not account 
for this patient’s arm involvement or dysphagia.
Metastatic Calcification
Two forms of cutaneous calcium deposition can 
occur in patients with renal disease: benign nod-
ular calcification and calciphylaxis. Both are caused 
by the precipitation of calcium and phosphate salts 
that is due to abnormal absorption, mobilization, 
or excretion of these ions, either alone or in com-
bination. In benign nodular calcification, large de-
posits accumulate in the skin and subcutis, par-
ticularly in periarticular locations.1 The process 
in our patient was more diffuse than would be 
expected with benign nodular calcification. Cal-
ciphylaxis is a process of ischemic necrosis of the 
skin and soft tissues due to increased vascular 
calcification,1,7 which manifests clinically as re-
ticulated, violaceous patches that can progress to 
bullae, necrosis, and ulceration.7 The lesions are 
exquisitely tender, unlike this patient’s lesions.
Nephrogenic Systemic Fibrosis
Nephrogenic systemic fibrosis is a relatively re-
cently recognized rapidly progressive fibrosing dis-
order of skin and internal organs that is seen in 
patients with kidney disease (estimated glomeru-
lar filtration rate, <30) who receive gadolinium-
containing contrast agents for MRI or magnetic 
resonance angiography.7-12 Almost all reported pa-
tients have received hemodialysis, peritoneal di-
alysis, or both, with peritoneal dialysis thought 
to confer a greater risk of the disorder than he-
modialysis.9,11,13 The condition is also associated 
with a history of thrombosis or coagulopathy, 
a vascular procedure or vascular injury, metabol-
ic acidosis, and erythropoietin use, although the 
role of these factors, if any, is unclear.3,7-12 Our 
patient had all these risk factors, although she 
was initially unaware of having been exposed to 
gadolinium.
Nephrogenic systemic fibrosis is characterized 
by swelling and symmetric, woody induration of 
the skin on the distal limbs that progresses prox-
imally and can also involve the trunk.3,7,9,11,13 As 
seen in this patient, the lesions are poorly de-
marcated, thickened plaques that range from 
erythematous to hyperpigmented and have an 
irregular leading edge that has been called 
“amoeboid.”7,9,11-13 Patients may note an itchy 
or painful quality to the affected skin.3,7,11 The 
surface may have a cobblestone or peau d’orange 
texture.3,11,12 Extracutaneous findings include 
scleral telangiectasias early and yellow scleral 
plaques later, as well as joint inflexibility and con-
tractures that result in decreased mobility and 
difficulty lifting or bending the legs.7,9,12,13 Sys-
temic fibrosis can affect the heart, lungs, skel-
etal muscle, and other organs.3,10,11 Our patient 
ultimately displayed many of these features.
It is believed that renal failure and metabolic 
acidosis increase the half-life of gadolinium in 
the body, allowing chelated gadolinium to disso-
ciate from its ligand and deposit in the skin and 
other tissues.3,8-11 Gadolinium triggers recruit-
ment of circulating fibrocytes to the skin and in-
ternal organs, resulting in fibrosis.8,10-13 Circu-
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lating fibrocytes are bone marrow–derived cells 
that are normally recruited to sites of tissue in-
jury to aid in wound healing.
Summ a r y
In summary, this patient with a history of renal 
failure, metabolic acidosis, recurrent thromboses, 
dialysis, erythropoietin use, and gadolinium ex-
posure presented with progressive leg swelling, 
hardening and hyperpigmentation of the skin of 
the legs and arms, and yellow scleral plaques. The 
differential diagnosis can be narrowed to eosino-
philic fasciitis and nephrogenic systemic fibro-
sis. In light of disease progression despite pred-
nisone and time and the lack of peripheral-blood 
eosinophilia, I believe the diagnosis is nephro-
genic systemic fibrosis.
There are no specific laboratory tests useful in 
diagnosing nephrogenic systemic fibrosis.9,13 
I would review previous skin-biopsy specimens 
with a dermatopathologist, including a complete 
discussion of the clinical features and a review 
of clinical photos if available. If these biopsy 
specimens are nondiagnostic, I would repeat the 
deep-wedge biopsy of the skin. I would also re-
peat the complete blood count, thyroid-function 
tests, and coagulopathy testing and would order 
serum and urine protein electrophoresis and tests 
for Scl-70 and anticentromere antibody to help 
rule out other diagnoses.
Dr. Nancy Lee Harris (Pathology): Dr. Kay, what 
was your thinking when you saw this patient?
Dr. Jonathan Kay: When I first saw the patient 
in rheumatologic consultation, her clinical pre-
sentation and improvement after treatment with 
prednisone, as well as the pathologist’s interpre-
tation of the wedge-biopsy specimen from her left 
thigh, led me to a diagnosis of eosinophilic fascii-
tis. I recommended that she taper the prednisone 
dose, keep her left leg mobile to prevent recurrence 
of deep venous thrombosis, and avoid excessive 
exercise, which has been thought to elicit eosino-
philic fasciitis disease activity.
Fifteen months later, she sought reevaluation 
because of hyperpigmentation and induration of 
the skin of her left forearm, left thigh, and both 
lower legs. At that time, she told me that she 
had learned that she had received gadodiamide, 
a gadolinium-containing contrast agent, at the 
time of MRI examinations on three occasions in 
the past.
On examination, the skin changes and scleral 
plaques were typical of nephrogenic systemic fi-
brosis, which had clearly progressed since her first 
consultation with me. The previous skin-biopsy 
specimen was reevaluated by the pathologist.
Clinic a l Di agnosis
Nephrogenic systemic fibrosis.
Dr . Da niel a K roshinsk y ’s 
Di agnosis
Nephrogenic systemic fibrosis.
Pathol o gic a l Discussion
Dr. Rosalynn M. Nazarian: Review of the specimen 
from the wedge biopsy of skin on the left thigh, 
performed 7 months before her first evaluation 
at this hospital, disclosed a superficial perivascu-
lar lymphocytic infiltrate, dermal edema, and in-
creased cellularity in the reticular dermis (Fig. 2A). 
Thickening of the interlobular septa in the sub-
cutaneous fat was seen, with a septal inflamma-
tory infiltrate consisting of histiocytes with oc-
casional multinucleated giant cells, lymphocytes, 
and eosinophils (Fig. 2B and inset). Focally, the 
septal infiltrate extended to involve the lobules in 
a perivascular and lacelike distribution (Fig. 2C). 
In other areas, there was marked thickening and 
fibrosis of the interlobular septa without an in-
flammatory infiltrate (Fig. 2D).
In the context of additional clinical informa-
tion, the previous slides of the biopsy specimens 
were reexamined at the patient’s second visit to 
the rheumatologist, with the addition of more 
stains. Further inspection of the fibrotic areas 
within the dermis and subcutaneous fat revealed 
a conspicuous increase in the density of spindle-
shaped fibroblasts and thickened collagen bundles 
with adjacent clefts; both are characteristic fea-
tures of nephrogenic systemic fibrosis14,15 (Fig. 
3A). The spindle-shaped cells were focally posi-
tive on immunohistochemical staining for smooth-
muscle actin (Fig. 3B), a feature suggestive of 
myofibroblastic differentiation, and strongly pos-
itive for CD34 (Fig. 3C), a feature consistent with 
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the characteristic dermal fibroblasts of nephro-
genic systemic fibrosis.14 Factor XIIIa–positive 
mononuclear cells were present throughout the 
dermis (Fig. 3D), which is another feature typical 
of (but not specific for) nephrogenic systemic fi-
brosis.14 Definitive diagnosis of nephrogenic sys-
temic fibrosis requires knowledge of the clinical 
history and examination of a deep punch-biopsy 
specimen that contains subcutaneous tissue. In 
addition to the features illustrated here, the der-
mal fibroblasts in nephrogenic systemic fibrosis 
are also highlighted by procollagen-I stains, and 
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Figure 2. Biopsy Specimen of Affected Skin on the Left Thigh, 7 Months before the Initial Evaluation (Hematoxylin 
and Eosin).
At low power, dermal edema and a superficial perivascular infiltrate is seen. Increased cellularity of the reticular der-
mis is also noted (Panel A). The subcutaneous fat deep in the section shown in Panel A reveals thickening of the 
septum, with a mixed inflammatory infiltrate that is consistent with a septal panniculitis (Panel B). At higher magni-
fication, it is apparent that the septal inflammatory infiltrate is composed of histiocytes with occasional multinucle-
ated giant cells, lymphocytes, and eos nophils (inset). Focally, the septal infiltrate has extended to involve the lobule 
in a perivascular and lacelike pattern (Panel C). In other areas, thickening and fibrosis of the interlobular septum are 
marked and reveal increased fibroblast cellularity without an ass ciated inflammatory infiltrate (Panel D).
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elongated dermal elastic fibers are highlighted by 
the Verhoeff–van Gieson stain.14 There may be 
mucin deposition and calcification, ossification, 
and osteoclast-like giant cells; giant cells were seen 
in this case.16,17
The histologic differential diagnosis of neph-
rogenic systemic fibrosis is broad (Table 1). Sclero-
myxedema and eosinophilic fasciitis are the clos-
est histologic mimics, since they share findings of 
increased fibroblast cellularity and the presence 
of factor XIIIa–positive histiocytic cells. Labora-
tory studies are helpful in differentiating these 
entities.20,21 In addition, “pools” of dermal mucin 
are often seen in scleromyxedema, whereas when 
mucin is present in nephrogenic systemic fibro-
sis, deposition is only focal.22 Normal skin is also 
included in the histologic differential diagnosis, 
since the histologic findings in early nephrogenic 
systemic fibrosis may be subtle. Differentiating 
nephrogenic systemic fibrosis from other entities 
involves consideration of the extent of dermal fi-
broblast cellularity, dermal mucin deposition, cyto-
logic atypia, and associated inflammatory infil-
trate, as well as of the immunohistochemical 
profile. In addition, knowledge of the clinical his-
tory, including renal function, presence or ab-
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Figure 3. Findings on Reexamination of the Skin-Biopsy Specimen, 14 Months after the Initial Evaluation.
Examination of a single high-power field of affected skin from the left thigh of this patient (Panel A, hematoxylin 
and eosin) reveals an increased number of spindle-shaped dermal fibroblasts (>69 fibroblast-cell nuclei per high-
power field) and thickened eosinophilic collagen bundles with adjacent clefts, as compared with normal skin from a 
healthy person (inset). The mean density of dermal fibroblast nuclei in patients with nephrogenic systemic fibrosis 
in a recent study was 69 nuclei per high-power field, as compared with 14 nuclei pe  high-power field in normal per-
sons.15 An immunohistochemical stain for smooth-muscle actin (Panel B) highlights the perivascular smooth mus-
cle (strong, diffuse brown staining) and shows focal positive staining in the spindle-shaped cells, which is sugges-
tive of myofibroblastic differentiation. An immunohistochemical stain for CD34 (Panel C) shows strong diffuse 
positivity in the spindle-shaped cells and highlights the endothelial cells within normal vascular channels. An immu-
nohistochemical stain for factor XIIIa (Panel D) shows positive staining of mononuclear cells throughout the dermis.
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sence of a history of gadolinium administration, 
and serologic studies, may be essential.
Discussion of M a nagemen t
Dr. Kay: A number of treatments for nephrogen-
ic systemic fibrosis, including topical and oral 
corticosteroids, selective histamine H2-receptor 
blockers, cyclosporine, other immunosuppressive 
therapy, and plasmapheresis, have proved to be 
ineffective.23,24 Several other treatments have been 
tried, with variable results. Thalidomide has re-
sulted in improvement in cutaneous changes in 
several patients with skin disease of recent on-
set; however, most patients with advanced skin 
disease did not have a response.25 Reductions in 
skin tightness and hardening have been described 
in patients with nephrogenic systemic fibrosis 
treated with extracorporeal photopheresis with 
ultraviolet A light.26-28 Single case reports have 
described improvement of skin changes with 
pentoxyphylline29 and intravenous sodium thio-
sulfate.30
Signaling by means of tyrosine kinase–medi-
ated pathways (transforming growth factor β1 
[TGFβ1], Abl, Kit, and platelet-derived growth fac-
tor [PDGF] receptor) may be important in the 
proliferation of fibroblasts and deposition of col-
lagen in tissues in nephrogenic systemic fibro-
sis.31-33 Imatinib mesylate selectively inhibits sig-
naling mediated by Abl, Kit, and the PDGF 
receptor32,34 and decreases both basal and TGFβ- 
and PDGF-induced type I collagen and fibronec-
tin synthesis by dermal fibroblasts.35 By inhibit-
ing signal transduction through the TGFβ and 
PDGF receptors, imatinib mesylate blocks the 
cellular response to these profibrotic cytokines, 
even if their tissue levels remain elevated. We ob-
served lessening of skin tethering and joint con-
tractures and reduced dermal and interlobular 
septal fibrosis and type I procollagen staining in 
two patients with nephrogenic systemic fibrosis 
who had been treated with imatinib mesylate for 
4 months.36 There is now an investigator-initiated 
phase 2, open-label pilot study of imatinib mesy-
late for the treatment of nephrogenic systemic 
fibrosis (ClinicalTrials.gov number, NCT00677092, 
supported by a grant from Novartis and by a grant 
[1 UL 1 RR025758-01] from the National Center 
for Research Resources to Harvard Clinical and 
Translational Science Center), in which patients 
are treated with imatinib mesylate (400 mg daily) 
for 4 months and then are observed for 2 months 
after stopping therapy. The primary outcome is 
the change in the modified Rodnan skin score 
(a standard outcome measure for skin disease in 
Table 1. Differential Diagnosis of Nephrogenic Systemic Fibrosis in the Skin.
Differential Diagnosis
Fibroblast 
Hyper-
cellularity
Dermal 
Mucin
Immunohistochemical 
Profile Distinguishing Feature
Nephrogenic systemic fibrosis Yes Yes CD34, factor XIIIa* Renal disease, high fibroblast count (approximately 
69 per high-power field)
Scleromyxedema Yes Yes CD34, factor XIIIa Paraproteinemia
Systemic sclerosis, morphea, and ex-
posure to toxins
No Yes Circulating autoantibodies, exposure to l-trypto-
phan* or rapeseed oil
Lichen sclerosus et atrophicus No No Circulating autoantibodies, Koebner’s phenomenon
Sclerodermatous chronic graft-versus-
host disease
No Yes Bone marrow transplant†
Eosinophilic fasciitis Yes No Factor XIIIa Peripheral eosinophilia, hypergammaglobulinemia
Malignant tumors
Dermatofibrosarcoma protuberans Yes No CD34* Cytologically malignant
Desmoplastic melanoma Yes No S100 Cytologically malignant
Normal skin Maybe Maybe Low fibroblast count (approximately 14 per high-
power field)
* Data are from Cowper et al.18
† Data are from Peñas et al.19
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patients with scleroderma that is calculated by 
summation of skin thickness in 17 body sites) 
from baseline to 4 months.
When I saw this patient the second time, I sug-
gested that she taper and eventually discontinue 
prednisone and consider participation in this 
study, which she elected to do.
Dr. Harris: The patient was not able to come to-
day because of complications of her kidney dis-
ease, but she sent me some comments that she 
thought might interest physicians: “First, do not 
ask a patient if he or she has been exposed to 
gadolinium. I was asked this and thought that it 
was either a form of asbestos or disease like tu-
berculosis. It was not until I was later asked if I 
had had any tests using contrast material that I 
made the connection. Second, if someone is not 
on dialysis, do not assume that he or she will not 
develop nephrogenic systemic fibrosis. I was not 
on dialysis until after my last exposure to gado-
linium. Finally, if you think a patient’s rash is due 
to Lyme disease and the test is negative multiple 
times, move on. I was tested about five times for 
Lyme disease.”
Are there any questions?
A Physician: What is the current recommenda-
tion for the use of gadolinium?
Dr. Kay: At this hospital, patients who are on 
dialysis or have a creatinine clearance of less than 
15 ml per minute per 1.73 m2 of body-surface 
area (stage 5 chronic kidney disease) do not receive 
gadolinium-containing contrast agents. Before ad-
ministering gadolinium, written informed consent 
is obtained from patients who have a creatinine 
clearance between 15 and 29 ml per minute (stage 
4 chronic kidney disease).
Dr. Harris: This is the third case of nephrogenic 
systemic fibrosis that we have discussed at one 
of these exercises,37,38 and in two cases, the di-
agnosis was initially missed on examination of 
skin-biopsy specimens. Although this patient’s 
initial clinical presentation was atypical, the di-
agnosis of nephrogenic systemic fibrosis was con-
sidered by the patient’s nephrologist and derma-
tologist. However, at the time of the biopsy, neither 
the suspicion of nephrogenic systemic fibrosis 
nor the history of chronic renal failure was com-
municated to the pathologist.
Dr. Lyn M. Duncan (Dermatopathology): Neph-
rogenic systemic fibrosis is a diagnosis that re-
lies on good communication between clinicians 
and pathologists and requires clinicopathologi-
cal correlation.
Dr. Harris: In dermatopathology, and also in 
other areas of pathology, the clinical history can 
be essential to establishing a specific pathologi-
cal diagnosis. Electronic medical records are prov-
ing helpful, since we can have the patient’s record 
open on a computer screen in front of us while 
we are looking at the slides.
A nat omic a l Di agnosis
Nephrogenic systemic fibrosis.
Presented at the postgraduate course Dermatopathology Up-
date, September 18, 2008, sponsored by the Harvard Medical 
School Office of Continuing Medical Education.
Dr. Kay (now at the Rheumatology Center, UMass Memorial 
Medical Center, and the Division of Rheumatology, University of 
Massachusetts Medical School — both in Worcester) reports re-
ceiving consulting fees from Amgen, Array BioPharma, Bracco, 
Centocor, EnzymeRx, Human Genome Sciences, Sanofi-Aventis, 
Savient, UCB, Roche, and Wyeth; an honorarium from Bristol-
Myers Squibb Norway; and grant support from Centocor, Genen-
tech, Novartis, and Pfizer. No other potential conflict of interest 
relevant to this article was reported.
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